This month, an experimental vaccine against Johnson and Johnson’s coronavirus began testing in humans after an early study showed it helped protect a group of primates with a single shot.
According to a study published in the medical journal Nature, all animals that experienced a pandemic six weeks after injection were immune, except for one that showed only low levels of the virus. The results prompted the medical firm to begin testing on humans last week in Belgium and earlier this week in the United States.
“We are pleased to see these preclinical data as they show that our candidate for the SARS-CoV-2 vaccine has elicited a strong response to antibodies and provided protection with a single dose,”; said Paul Stoffels, chief research officer of Johnson and Johnson. “The results give us confidence when we promote vaccine development and parallel production in parallel …”.
The company said it intends to begin the final phase of the trial in September and that 1,045 people will take part in the trial.
Johnson & Johnson competes against a number of other companies competing for the vaccine, and although other firms are growing faster, Johnson & Johnson’s ability to produce an immune response in a single dose may bring it an advantage in the use of vaccination.
The company did not announce the estimated price for its shot, but said it was increasing production to try to provide more than 1 billion doses to people worldwide.